BACKGROUND: Trastuzumab improves the survival of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). The incidence and long-term impact of trastuzumab-related cardiotoxicity in the community setting is of great clinical importance. MATERIAL AND METHODS: Patients with HER2-positive BC treated with (neo)adjuvant trastuzumab were retrospectively evaluated. Cardiotoxicity was defined as cardiac death or absolute decrease in left ventricular ejection fraction of at least 10% to a value less than 50%, or symptomatic heart failure. RESULTS: We evaluated 237 patients: median age 53 years (range 27-83 years). 40.5% of these patients had received neoadjuvant and 59.5% adjuvant chemotherapy. The majority (83.9%) were treated with an anthracycline-based regimen. Median exposure to trastuzumab was 8 months (range 2-12 months). Cardiotoxicity was diagnosed in 20.2%, but symptoms only occurred in 3.8%. 41.6% recovered cardiac function. None of the risk factors were associated with cardiotoxicity. CONCLUSION: The incidence of trastuzumab-related cardiotoxicity found in this study was slightly higher than those reported in randomized clinical trials. Nevertheless, most patients were asymptomatic. We describe the cardiac outcomes of a non-selected population, which possibly reflects those found in the 'real world'. The risks versus benefits of trastuzumab use remain in favor of treatment, but cardiotoxicity should be monitored.
BACKGROUND:Trastuzumab improves the survival of patients with humanepidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). The incidence and long-term impact of trastuzumab-related cardiotoxicity in the community setting is of great clinical importance. MATERIAL AND METHODS:Patients with HER2-positive BC treated with (neo)adjuvant trastuzumab were retrospectively evaluated. Cardiotoxicity was defined as cardiac death or absolute decrease in left ventricular ejection fraction of at least 10% to a value less than 50%, or symptomatic heart failure. RESULTS: We evaluated 237 patients: median age 53 years (range 27-83 years). 40.5% of these patients had received neoadjuvant and 59.5% adjuvant chemotherapy. The majority (83.9%) were treated with an anthracycline-based regimen. Median exposure to trastuzumab was 8 months (range 2-12 months). Cardiotoxicity was diagnosed in 20.2%, but symptoms only occurred in 3.8%. 41.6% recovered cardiac function. None of the risk factors were associated with cardiotoxicity. CONCLUSION: The incidence of trastuzumab-related cardiotoxicity found in this study was slightly higher than those reported in randomized clinical trials. Nevertheless, most patients were asymptomatic. We describe the cardiac outcomes of a non-selected population, which possibly reflects those found in the 'real world'. The risks versus benefits of trastuzumab use remain in favor of treatment, but cardiotoxicity should be monitored.
Entities:
Keywords:
Adjuvant therapy; Breast cancer; Cardiotoxicity; Trastuzumab
Authors: Marion Procter; Thomas M Suter; Evandro de Azambuja; Urania Dafni; Veerle van Dooren; Susanne Muehlbauer; Miguel Angel Climent; Ernst Rechberger; Walter Tsang-Wu Liu; Mazakasu Toi; R Charles Coombes; David Dodwell; Olivia Pagani; Jorge Madrid; Marcia Hall; Shin-Cheh Chen; Christian Focan; Michael Muschol; Dirk J van Veldhuisen; Martine J Piccart-Gebhart Journal: J Clin Oncol Date: 2010-06-07 Impact factor: 44.544
Authors: Aman U Buzdar; Vicente Valero; Nuhad K Ibrahim; Deborah Francis; Kristine R Broglio; Richard L Theriault; Lajos Pusztai; Marjorie C Green; Sonja E Singletary; Kelly K Hunt; Aysegul A Sahin; Francisco Esteva; William F Symmans; Michael S Ewer; Thomas A Buchholz; Gabriel N Hortobagyi Journal: Clin Cancer Res Date: 2007-01-01 Impact factor: 12.531
Authors: Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown Journal: N Engl J Med Date: 2011-10-06 Impact factor: 91.245
Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Edward H Romond; Jong-Hyeon Jeong; Priya Rastogi; Sandra M Swain; Charles E Geyer; Michael S Ewer; Vikas Rathi; Louis Fehrenbacher; Adam Brufsky; Catherine A Azar; Patrick J Flynn; John L Zapas; Jonathan Polikoff; Howard M Gross; David D Biggs; James N Atkins; Elizabeth Tan-Chiu; Ping Zheng; Greg Yothers; Eleftherios P Mamounas; Norman Wolmark Journal: J Clin Oncol Date: 2012-09-17 Impact factor: 44.544
Authors: A L Jones; M Barlow; P J Barrett-Lee; P A Canney; I M Gilmour; S D Robb; C J Plummer; A M Wardley; M W Verrill Journal: Br J Cancer Date: 2009-03-10 Impact factor: 7.640